Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Although these products might confer significant advantages over the currently available treatments, there is still a huge unmet need for drugs that prevent the progression of COPD. Companies are ...

They’ll determine the best dosage to fit your needs ... it may take a few weeks before you notice your COPD symptoms beginning to ease. This is because the drug works over time to slowly ...

reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process. ICER isn't officially involved in the price negotiations introduced ...

Asthma–chronic obstructive pulmonary disease (COPD ... then to determine the best available therapy. The authors discuss the array of existing and emerging classes of drugs that could benefit ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.